$1.19
2.59% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US6294441000
Symbol
NRXP
Sector
Industry

NRX Pharmaceuticals Inc Stock price

$1.19
-0.01 0.83% 1M
-2.04 63.16% 6M
-3.41 74.13% YTD
-2.06 63.38% 1Y
-60.81 98.08% 3Y
-104.91 98.88% 5Y
-94.81 98.76% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.03 2.59%
ISIN
US6294441000
Symbol
NRXP
Sector
Industry

Key metrics

Market capitalization $12.79m
Enterprise Value $17.81m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-20.48m
Cash position $1.90m
EPS (TTM) EPS $-2.15
P/E forward negative
Short interest 7.69%
Show more

Is NRX Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

NRX Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a NRX Pharmaceuticals Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a NRX Pharmaceuticals Inc forecast:

Buy
100%

Financial data from NRX Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
-0.01 -0.01
0% 0%
-
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense 7.70 7.70
50% 50%
-
- -
-
-
- Depreciation and Amortization 0.01 0.01
0% 0%
-
EBIT (Operating Income) EBIT -20 -20
38% 38%
-
Net Profit -20 -20
43% 43%
-

In millions USD.

Don't miss a Thing! We will send you all news about NRX Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NRX Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
one day ago
On track to file New Drug Applications (NDAs) for NRX-100 (IV Ketamine) in treating suicidal ideation in depression, including bipolar depression and NRX-101 (Oral D-Cycloserine/Lurasidone) for Accelerated Approval in bipolar depression with suicidality or akathisia by year end 2024 with 2025 PDUFA date forecast. HOPE Therapeutics acquiring Interventional Psychiatry Clinics; key to developing a...
Neutral
PRNewsWire
3 days ago
WILMINGTON, Del. , Nov. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will reschedule its third quarter and year to date 2024 results conference call to Monday November 18, 2024 at 4:30pm ET, to accommodate any additional corporate news.
Neutral
PRNewsWire
8 days ago
WILMINGTON, Del.  , Nov. 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter and year to date 2024 financial results after the market closes on Thursday, November 14, 2024, via press release, which will be available on the Company's website at h...
More NRX Pharmaceuticals Inc News

Company Profile

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Head office United States
CEO Jonathan Javitt
Founded 2017
Website www.nrxpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today